CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 682 enrolled
Drug / intervention
Temozolomide +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00723827
NCT00723827N/ACompleted

Temodal (Temozolomide) Post Marketing Surveillance Protocol

Merck Sharp & Dohme LLC·observational·Posted Jul 29, 2008·Updated Jan 30, 2015

In Brief

An observational study evaluating Temozolomide and Radiotherapy for Glioblastoma and 2 related conditions. Completed, enrolled 682 participants.

Detailed Summary

The purpose of this surveillance is to evaluate the postmarketing safety and efficacy of Temodal capsule (temozolomide) under actual conditions of use, and to understand some of the following points that are in question and doubt: * Incidence of adverse events under actual conditions of use (Serious and Nonserious Adverse Events); * Adverse Drug Reactions not shown in the directions for use (will be stated as Unexpected Adverse Reaction); * Adverse Event caused by misuse, abuse, or drug interactions; * Other information concerned with safety or efficacy.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
Countries--
Collaborators--

Timeline

N/ACompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJul 29, 2008
Enrollment StartMar 1, 2008
Primary CompletionSep 1, 2011
TodayJul 2, 2026
Enrollment to primary: 3.5 yearsPosted 17.9 years ago

Interventions

Temozolomidedrug

Administration of temozolomide based on the product labeling.

Radiotherapyradiation

Radiotherapy given concomitantly with temozolomide for newly diagnosed glioblastoma multiforme.